Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models

Surgical Oncology Clinics of North America
G M BeasleyDouglas Tyler

Abstract

A common treatment modality for in transit melanoma of the extremity has been hyperthermic isolated limb perfusion (HILP) with melphalan and more recently, isolated limb infusion (ILI) with melphalan with or without dactinomycin. Research in the area has primarily focused on maximizing drug delivery through a better understanding of pharmacokinetics while maintaining acceptable levels of toxicity. Although other agents continue to be explored as regional chemotherapy agents, melphalan is currently the drug of choice, although temozolomide has demonstrated promising preclinical results. Resistance mechanisms to melphalan and melphalan pharmacokinetics are studied using animal models of HILP and ILI. The addition of modulators to overcome resistance to the traditional chemotherapy regimen may ultimately improve the clinical response in patients with in-transit melanoma of the extremity.

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R N ScottA J McKay
Feb 1, 1991·International Journal of Radiation Biology·B V HarmonG C Gobé
Feb 1, 1991·International Journal of Radiation Oncology, Biology, Physics·D W SiemannA Beikirch
Jun 1, 1983·The Australian and New Zealand Journal of Surgery·G J KourtesisG W Milton
Aug 17, 1994·Biochemical Pharmacology·R S Fernandes, T G Cotter
Aug 1, 1997·Archives of Surgery·J F ThompsonP C Kam
Apr 21, 1998·Seminars in Surgical Oncology·D LiénardF J Lejeune
Mar 13, 2002·Annals of Surgical Oncology·Per LindnérJohn F Thompson
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jun 25, 2002·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·M Urano, C C Ling
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulrike SteinPeter Hohenberger
Jul 10, 2003·The Lancet Oncology·Alexander M M EggermontTimo L M ten Hagen
Nov 6, 2003·American Journal of Surgery·Tsung-Yen ChengDouglas Tyler
Aug 10, 2004·Surgery·Elizabeth G GrubbsDouglas S Tyler
Nov 4, 2004·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J J BonenkampP C A Kam
Nov 4, 2004·Journal of the National Cancer Institute·Flavia BrunsteinTimo L M ten Hagen
Dec 31, 2005·Annals of the New York Academy of Sciences·Keiran S M Smalley, Meenhard Herlyn
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sae Hee KoDouglas S Tyler
Apr 14, 2006·Neoplasia : an International Journal for Oncology Research·Oliver ThewsMichael Gekle
Aug 10, 2006·Cancer Immunology, Immunotherapy : CII·Flavia BrunsteinTimo L M ten Hagen
Oct 25, 2006·Annals of Surgery·Chandrakala MenonDouglas L Fraker

❮ Previous
Next ❯

Citations

Apr 13, 2012·The Journal of Surgical Research·Minhyung KimJoseph J Skitzki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Charles M BalchVernon K Sondak
Journal of Surgical Oncology
Ulrike LeiterClaus Garbe
Plastic and Reconstructive Surgery and the Transplantation Bulletin
O CREECHE T KREMENTZ
© 2022 Meta ULC. All rights reserved